- Home
- BFRG vs SYBX Comparison
BFRG vs SYBX Comparison
Compare BFRG & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- SYBX
- Stock Information
- Founded
- BFRG 2017
- SYBX N/A
- Country
- BFRG United States
- SYBX United States
- Employees
- BFRG N/A
- SYBX N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- SYBX Health Care
- Exchange
- BFRG Nasdaq
- SYBX Nasdaq
- Market Cap
- BFRG 16.4M
- SYBX 13.9M
- IPO Year
- BFRG 2023
- SYBX N/A
- Fundamental
- Price
- BFRG $1.51
- SYBX $1.63
- Analyst Decision
- BFRG
- SYBX
- Analyst Count
- BFRG 0
- SYBX 0
- Target Price
- BFRG N/A
- SYBX N/A
- AVG Volume (30 Days)
- BFRG 204.8K
- SYBX 83.1K
- Earning Date
- BFRG 08-06-2025
- SYBX 08-07-2025
- Dividend Yield
- BFRG N/A
- SYBX N/A
- EPS Growth
- BFRG N/A
- SYBX N/A
- EPS
- BFRG N/A
- SYBX 0.21
- Revenue
- BFRG N/A
- SYBX N/A
- Revenue This Year
- BFRG N/A
- SYBX N/A
- Revenue Next Year
- BFRG N/A
- SYBX N/A
- P/E Ratio
- BFRG N/A
- SYBX $7.63
- Revenue Growth
- BFRG N/A
- SYBX N/A
- 52 Week Low
- BFRG $1.23
- SYBX $0.90
- 52 Week High
- BFRG $4.84
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- BFRG 49.22
- SYBX 71.09
- Support Level
- BFRG $1.44
- SYBX $1.53
- Resistance Level
- BFRG $1.58
- SYBX $1.96
- Average True Range (ATR)
- BFRG 0.07
- SYBX 0.17
- MACD
- BFRG 0.01
- SYBX 0.03
- Stochastic Oscillator
- BFRG 46.94
- SYBX 63.75
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.